About ACHV

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Primary Exchange: NASDAQ
SIC In Vitro & In Vivo Diagnostic Substances
NAICS In-Vitro Diagnostic Substance Manufacturing

ACHV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 16.5 B 1.65381E+10 3,387 3387 0.0% 0 2 K 2385
WMCR Invesco Wilshire Micro-Cap ETF 21.7 M 2.17E+07 1,083 1083 0.01% 8E-05 2 K 1725

Wait, Before You Leave...